Stock Track | AtriCure (ATRC) Soars 32.46% in Pre-Market on Strong 2025 Results and 2026 Guidance
Stock Track
Jan 15
AtriCure's stock surged 32.46% in pre-market trading on Thursday following the release of its preliminary 2025 results and optimistic 2026 guidance. The company projected revenues between US$600 million and US$610 million for 2026, alongside expectations of positive adjusted EBITDA, net income, and cash flow.
The positive outlook was further bolstered by the extension of AtriCure's asset-based revolving credit facility, which now offers improved terms and lower interest costs. This financial flexibility is expected to support the company's commercial efforts and clinical programs, including the completion of enrollment in a key clinical trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.